Greg Zante serves as the Chief Financial Officer at Viking Therapeutics Inc., a position he has held since joining the company in 2014. With a robust background in finance and biotechnology, Zante has been instrumental in steering Viking Therapeutics through various stages of growth and development. Before joining Viking, he held significant roles at other biotech firms, including serving as the CFO at Ambit Biosciences, where he played a key role in the company's successful acquisition by Daiichi Sankyo in 2014. Zante's expertise in financial strategy and corporate development has been vital in navigating Viking Therapeutics' journey towards advancing its therapeutic pipeline. At Viking Therapeutics, Zante's primary responsibilities include overseeing the company's financial operations, strategic planning, and investor relations. Under his leadership, the company has made significant strides in its clinical programs, particularly in the development of novel therapies for metabolic and endocrine disorders. Zante has been pivotal in securing funding and managing the company's resources effectively, ensuring that Viking remains at the forefront of innovation in the biotech industry. His strategic financial planning has enabled the company to undertake ambitious research projects and clinical trials, positioning Viking Therapeutics as a leader in its field. In addition to his professional achievements, Zante holds a Bachelor of Science degree in Business Administration from the University of Southern California and an MBA from the UCLA Anderson School of Management. His educational background, combined with his extensive experience in the biotech sector, has equipped him with the skills necessary to drive Viking Therapeutics' financial and strategic initiatives forward. Zante's dedication to the company's mission and his ability to foster strong relationships with investors and stakeholders have been crucial to Viking Therapeutics' ongoing success and growth.